Future anti-HBV strategies

Liver International

Volumn 37, Issue , 2017, Pages 40-44

  Gane, Edward J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

cccDNA silencing; core inhibitor; HBV Cure; immunomodulator; siRNA

Indexed keywords

ANTIVIRUS AGENT; CHECKPOINT KINASE INHIBITOR; HEPATITIS VACCINE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; CIRCULAR DNA; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS B; DISEASE ERADICATION; DNA IMMUNIZATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; GENE SILENCING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LIVER CELL NUCLEUS; LYMPHOCYTE FUNCTION; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE EXHAUSTION; VIRION; VIRUS LOAD; VIRUS NUCLEOCAPSID; BLOOD; DRUG DESIGN; DRUG EFFECTS; HEPATITIS B VIRUS; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, CIRCULAR; DRUG DESIGN; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 85007574117     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13304     Document Type: Review

References (22)

1. Warner N, Locarninini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88–98.
2. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev. 2005;5:215–229.
3. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol. 2001;34:917–921.
4. Vandepapeliere P, Lau GKK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by anti-viral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25:8585–8597.
5. Gaggar A, Coeshott C, Apelian D, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine. 2014;32:4925–4931.
6. Lok A, Pan C, Han S-H, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65:509–516.
7. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144:1508–1517.
8. Gane E, Lim Y, Gordon S, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015;63:320–328.
9. Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol. 2009;21:179–186.
10. Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res. 2011;60:47–53.
11. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 2014;10:e1003856.
12. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64.
13. Quinet J, Jamard C, Vaillant A, Cova L. Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-CA and nucleoside analogues against chronic hepatitis B. J Hepatol. 2016;64(Suppl 2):S285.
14. Klumppa K, Lama A, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. PNAS. 2015;112:15196–15201.
15. Gane EJ, Schwabe S, Walker K, et al. Phase 1a safety and pharmacokinetics of NVR 3–778, a potential first-in-class HBV core inhibitor. Hepatology 2014;60:LB19.
16. Yuen MF, Kim DL, Weilert F, et al. Phase 1b efficacy and safety of NVR 3–778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection. Hepatology. 2015;62:385A.
17. Xu Z, Chavez D, Guerraet B, et al. Treatment of chronically HBV-infected chimpanzees with RNA interference therapeutic ARC-520 led to potent reduction of viral mRNA, DNA and proteins without observed drug resistance. J Hepatol. 2016;64(Suppl 2):S398.
18. Yuen M, Chan H, Liu K, et al. Differential reductions in viral antigens expressed from cccDNA vs integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520. J Hepatol. 2016;64(Suppl 2):S390.
19. Nakazono K, Ito Y, Wu C, Wu G. Inhibition of Hepatitis B Virus Replication by Targeted Pretreatment of Complexed Antisense DNA In Vitro. Hepatology. 1996;23:1297–1303.
20. Ramanam V, Shlomai A, Cox D, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Nature 2015;5: 10833.
21. Wang CC, Shen YC, Wu FY, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids. 2014;3:e186.
22. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B:a modelling study. Lancet Infect Dis 2016;16:1399–1408.